DT reports Q4 on Feb 1. MBU may not grow much this year, yet organic SBU-driven recovery and recent ...
Consti reports its Q4 figures on 2nd of February. We expect a solid finish to the year despite conti...
Rapportkommentar Diamyds rapport för det första kvartalet 2023/2024 var i linje med våra förväntning...
Neutralt resultat givet förutsättningarna BE Group rapporterade ett i våra ögon neutralt resultat gi...
Redeye updates our outlook after Q4 2023. XVIVO delivers improved gross margins with a softer organi...
Vera has a BAFF/APRIL B-Cell modulator based IgAN candidate called Atacicept, which has delivered 2b...
EcoRub har idag publicerat bolagets Q4-rapport och visar på fortsatta framsteg.
Acconeer yesterday announced a design win of over SEK 50m for access control related to a major Japa...
Redeye comments on Mestro’s launch of its Data-as-a-Service (DaaS) solution.
XVIVO delivers a soft 12% organic growth in the last quarter of 2023 (based on CER excluding acquisi...
Redeye believes Sdiptech’s acquisition of JR Industries looks solid.
We update our estimates ahead of Arise’s Q4 report on the back of the recently published production ...
Q4'23 results due 6 February Already pre-announced strong sales for Oct-Nov Fully focused US orthobi...
Prel. Q4 figures: EE 3.7m, revenue SEK 37m, EBIT SEK 15.
Chordate Medical AB (”Chordate” eller ”bolaget”) är verksamma inom medicinteknikbranschen, och bolag...
Vitrolife provides an update ahead of the total Q4 due on 2 February.
Encouraged by the acquisition of Kammac, we raise adjusted EBIT by 14-15% for 2024E-25E ahead of Ela...
Starts deploying its cash pile... ...and executing on M&A-focused growth strategy.
Q4e: sales SEK 574m, -3% y-o-y, SEK 60m material sales in comps Tougher comps and an EMS slowdown af...
SEK 4.3bn impairment charge of Igenomix 1.6% beat on preliminary Q4 adj EBITDA Minor positive earnin...
